-+ 0.00%
-+ 0.00%
-+ 0.00%

EMA accepts Teva application for monthly olanzapine injectable schizophrenia treatment

PUBT·05/21/2026 16:30:25
Listen to the news
EMA accepts Teva application for monthly olanzapine injectable schizophrenia treatment
  • EMA accepted Teva’s marketing authorization application for TEV-’749, a long-acting injectable olanzapine for schizophrenia in adults.
  • The candidate is a once-every-four-weeks subcutaneous formulation designed to improve adherence.
  • Medincell is the partner on the program; TEV-’749 is not yet approved by any regulator.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605211230OMX_____CNEWS_EN_GNW1001183365_en) on May 21, 2026, and is solely responsible for the information contained therein.